Therapeutics / News / PR Newswire / biotechnology / Clinical Trials / Medical Discoveries / Health Care / Hospitals / Medical / Pharmaceuticals

Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting

Posted on: Oct 1, 2018   |   Posted by: Biotech Mag Top

Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with...